Neuroendocrine hormones as prognostic biomarkers in the setting of acute stroke: Overcoming the major hurdles

Expert Review of Neurotherapeutics

Volumn 14, Issue 12, 2014, Pages 1391-1403

  Bustamante, Alejandro ^a   Garcia Berrocoso, Teresa ^a   Llombart, Victor ^a   Simats, Alba ^a   Giralt, Dolors ^a   Montaner, Joan ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

biomarker; copeptin; meta analysis; neuroendocrine marker; outcome; prognosis; stroke; systematic review

Indexed keywords

BIOLOGICAL MARKER;

BLOOD; CLINICAL TRIAL (TOPIC); HUMAN; META ANALYSIS; METABOLISM; NEUROSECRETION; PREDICTIVE VALUE; PROGNOSIS; STROKE;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; NEUROSECRETORY SYSTEMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STROKE;

EID: 84914158831     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2014.977867     Document Type: Review

References (99)

1. European Registers of Stroke (EROS) Investigators. Heuschmann PU, Di Carlo A, Bejot Y, et al. Incidence of stroke in Europe at the beginning of the 21st century. Stroke 2009;40(5):1557-63
2. Nichols M, Townsend N, Luengo-Fernandez R, et al. European Cardiovascular Disease Statistics 2012. European Heart Network; Brussels: European Society of Cardiology; Sophia Antipolis: 2012
3. Murray JL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2197-223
4. Counsell C, Dennis M. Systematic review of prognostic models in patients with acute stroke. Cerebrovasc Dis 2001;12(3):159-70.
5. Teale EA, Forster A, Munyombwe T, Young JB. A systematic review of case-mix adjustment models for stroke. Clin Rehabil 2012;26(9):771-86
6. Ntaios G, Faouzi M, Ferrari J, et al. An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score. Neurology 2012;78(24): 1916-22
7. Strbian D, Seiffge DJ, Breuer L, et al. Validation of the DRAGON score in 12 stroke centers in anterior and posterior circulation. Stroke 2013;44(10):2718-21
8. Saposnik G, Raptis S, Kapral MK, et al. on behalf of the investigators of the registry of the Canadian Stroke Network and the Stroke Outcomes Research Canada Working Group. The iScore predicts poor functional outcomes early after hospitalization for an acute ischemic stroke. Stroke 2011;42(12): 3421-8
9. O'Donnell MJ, Fang J, D'Uva C, et al. for the investigators of the registry of the Canadian Stroke Network. The PLAN score. A bedside prediction rule for death and severe disability following acute ischemic stroke. Arch Intern Med 2012; 172(20):1548-56
10. Saposnik G, Guzik AK, Reeves M, et al. Stroke prognostication using age and NIH stroke scale: SPAN-100. Neurology 2013; 80(1):21-8
11. Martínez-Morillo E, García-Hernández P, Begcevic I, et al. Identification of novel biomarkers of brain damage in patients with hemorrhagic stroke by integrating bioinformatics and mass spectrometry-based proteomics. J Proteome Res 2014;13(2): 969-81
12. Mellick GD, Silburn PA, Sutherland GT, Siebert GA. Exploiting the potential of molecular profiling in Parkinson's disease: current practice and future probabilities. Expert Rev Mol Diagn 2010;10(8):1035-50
13. Abu-Asab MS, Chaouchi M, Alesci S, et al. Biomarkers in the age of omics: time for a systems biology approach. OMICS 2011; 15(3):105-12
14. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 2009;40(5):e380-9.
15. Katan M, Elkind MSV. Inflammatory and neuroendocrine biomarkers of prognosis after ischemic stroke. Expert Rev Neurother 2011;11(2):225-39.
16. Hasan N, McColgan P, Bentley P, et al. Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review. Br J Clin Pharmacol 2012;74(2):230-40
17. Smith CJ, Emsley H, Gavin CM, et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 2004;4:2
18. Montaner J, Fernandez-Cadenas I, Molina CA, et al. Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 2006; 37(5):1205-10
19. Rosell A, Cuadrado E, Alvarez-Sabín J, et al. Caspase-3 is related to infarct growth after human ischemic stroke. Neurosci Lett 2008;430(1):1-6
20. Yang XY, Gao S, Ding J, et al. Plasma D-dimer predicts short-term poor outcome after acute ischemic stroke. PLoS One 2014; 9(2):e89756
21. Montaner J, Alvarez-Sabín J, Molina C, et al. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001;32(8):1759-66
22. Shibazaki K, Kimura K, Okada Y, et al. Plasma brain natriuretic peptide as an independent predictor of in-hospital mortality after acute ischemic stroke. Intern Med 2009;48(18):1601-6
23. García-Berrocoso T, Giralt D, Bustamante A, et al. B-type natriuretic peptides and mortality after stroke: a systematic review and meta-analysis. Neurology 2013;81(23):1976-85.
24. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27(2):157-72.
25. Pickering JW, Endre ZH. New metrics for assessing diagnostic potential of candidate biomarkers. Clin J Am Soc Nephrol 2012; 7(8):1355-64
26. Whiteley W, Wardlaw J, Dennis M, et al. The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke 2012; 43(1):86-91
27. García-Berrocoso T, Giralt D, Bustamante A, et al. Role of beta-defensin 2 and interleukin-4 receptor as stroke outcome biomarkers. J Neurochem 2014; 129(3):463-72
28. Salat D, Penalba A, García-Berrocoso T, et al. Immunological biomarkers improve the accuracy of clinical risk models of infection in the acute phase of ischemic stroke. Cerebrovasc Dis 2013;35(3):220-7
29. Meyer S, Strittmatter M, Fischer C, et al. Lateralization in autonomic dysfunction in ischemic stroke involving the insular cortex. Neuroreport 2004;15(2):357-61
30. Feibel JH, Hardy PM, Campbell RG, et al. Prognostic value of the stress response following stroke. JAMA 1977;238(13): 1374-6
31. Sander D, Winbeck K, Klingelhöfer J, et al. Prognostic relevance of pathological sympathetic activation after acute thromboembolic stroke. Neurology 2001; 57(5):833-8
32. Urra X, Cervera A, Obach V, et al. Monocytes are major players in the prognosis and risk of infection after acute stroke. Stroke 2009;40(4):1262-8
33. Chamorro A, Amaro S, Vargas M, et al. Catecholamines, infection, and death in acute ischemic stroke. J Neurol Sci 2007; 252(1):29-35
34. Klehmet J, Harms H, Richter M, et al. Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial. Neuroscience 2009;158(3):1184-93
35. Hjemdahl P. Plasma catecholamines - analytical challenges and physiological limitations. Baillieres Clin Endocrinol Metab 1993;7(2):307-53
36. Montaner J, Perea-Gainza M, Delgado P, et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008;39(8):2280-7
37. Rodríguez-Yáñez M, Sobrino T, Blanco M, et al. High serum levels of pro-brain natriuretic peptide (pro BNP) identify cardioembolic origin in undetermined stroke. Dis Markers 2009;26(4):189-95
38. Frontzek K, Fluri F, Siemerkus J, et al. Isolated insular strokes and plasma MR-proANP levels are associated with newly diagnosed atrial fibrillation: a pilot study. PLoS One 2014;9(3):e92421
39. Santamarina E, Penalba A, García-Berrocoso T, et al. Biomarker level improves the diagnosis of embolic source in ischemic stroke of unknown origin. J Neurol 2012;259(12):2538-45
40. Rodríguez-Yáñez M, Arias-Rivas S, Santamaría-Cadavid M, et al. High pro-BNP levels predict the occurrence of atrial fibrillation after cryptogenic stroke. Neurology 2013;81(5):444-7
41. Nogami M, Shiga J, Takatsu A, et al. Immunohistochemistry of atrial natriuretic peptide in brain infarction. Histochem J 2001;33(2):87-90
42. Mäkikallio AM, Mäkikallio TH, Korpelainen JT, et al. Natriuretic peptides and mortality after stroke. Stroke 2005; 36(5):1016-20
43. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004;50(1):234-6
44. Alehagen U, Dahlström U, Rehfeld JF, Goetze JP. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure. J Card Fail 2013;19(1):31-9
45. Seronde MF, Gayat E, Logeart D, et al. Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure. Int J Cardiol 2013;168(4):3404-11
46. Katan M, Fluri F, Schuetz P, et al. Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. J Am Coll Cardiol 2010;56(13): 1045-53.
47. Fischer M, Katan M, Morgenthaler NG, et al. The prognostic value of midregional proatrial natriuretic peptide in patients with hemorrhagic stroke. Cerebrovasc Dis 2014; 37(2):128-33
48. Etgen T, Baum H, Sander K, Sander D. Cardiac troponins and N-terminal pro-brain natriuretic peptide in acute ischemic stroke do not relate to clinical prognosis. Stroke 2005;36(2):270-5
49. Jensen JK, Mickley H, Bak S, et al. Serial measurements of N-terminal pro-brain natriuretic peptide after acute ischemic stroke. Cerebrovasc Dis 2006;22(5-6): 439-44
50. Sharma JC, Ananda K, Ross I, et al. N-terminal probrain natriuretic peptide levels predict short-term poststroke survival. J Stroke Cerebrovasc Dis 2006;15(3):121-7
51. Koenig MA, Puttgen HA, Prabhakaran V, et al. B-type natriuretic peptide as a marker for heart failure in patients with acute stroke. Intensive Care Med 2007;33(9): 1587-93
52. Idris I, Hill R, Ross I, Sharma JC. N-terminal probrain natriuretic peptide predicts 1-year mortality following acute stroke: possible evidence of occult cardiac dysfunction among patients with acute stroke. Age Ageing 2010;39(6):752-5
53. Shibazaki K, Kimura K, Iguchi Y, et al. Plasma brain natriuretic peptide predicts death during hospitalization in acute ischaemic stroke and transient ischaemic attack patients with atrial fibrillation. Eur J Neurol 2011;18(1):165-9
54. Rost NS, Biffi A, Cloonan L, et al. Brain natriuretic peptide predicts functional outcome in ischemic stroke. Stroke 2012; 43(2):441-5
55. Hajdinjak E, Klemen P, Grmec S. Prognostic value of a single prehospital measurement of N-terminal pro-brain natriuretic peptide and troponin T after acute ischaemic stroke. J Int Med Res 2012; 40(2):768-76
56. Chen X, Zhan X, Chen M, et al. The prognostic value of combined NT-pro-BNP levels and NIHSS scores in patients with acute ischemic stroke. Intern Med 2012; 51(20):2887-92
57. Kimura K, Shibazaki K, Iguchi Y, et al. The combination of elevated BNP and AF as a predictor of no early recanalization after IV-t-PA in acute ischemic stroke. J Neurol Sci 2010;290(1-2):37-40
58. Modrego PJ, Boned B, Berlanga JJ, Serrano M. Plasmatic B-type natriuretic peptide and C-reactive protein in hyperacute stroke as markers of CT-evidence of brain edema. Int J Med Sci 2008;5(1):18-23
59. Montaner J, García-Berrocoso T, Mendioroz M, et al. Brain natriuretic peptide is associated with worsening and mortality in acute stroke patients but adds no prognostic value to clinical predictors of outcome. Cerebrovasc Dis 2012;34(3):240-5
60. Stewart LA, Parmar MKB. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993;341(8842): 418-22
61. Leone MA, Brainin M, Boon P, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2012. Eur J Neurol 2013; 20(3):410-19
62. Tzoulaki I, Siontis KC, Evangelou E, Ioannidis JP. Bias in associations of emerging biomarkers with cardiovascular disease. JAMA Intern Med 2013;173(8): 664-71
63. Whiteley W, Tseng MC, Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke. A systematic review. Stroke 2008;39(10):2902-9
64. Meisel C, Schwab JM, Prass K, et al. Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci 2005;6(10):775-86
65. Egea-Guerrero JJ, Muñoz-Sánchez MA, Murillo-Cabezas F. Immune depression after spontaneous subarachnoid hemorrhage. Med Intensiva 2014. [Epub ahead of print]
66. Wester P, Puu G, Reiz S, et al. Increased monoamine metabolite concentrations and cholinesterase activities in cerebrospinal fluid of patients with acute stroke. Acta Neurol Scand 1987;76(6):473-9
67. Assayag EB, Shenhar-Tsarfaty S, Ofek K, et al. Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality. Mol Med 2010;16(7-8):278-86
68. Jurney TH, Cockrell JL Jr, Lindberg JS, et al. Spectrum of serum cortisol response to ACTH in ICU patients-correlation with degree of illness and mortality. Chest 1987; 92(2):292-5
69. Wade CE, Lindberg JS, Cockrell JL, et al. Upon-admission adrenal steroidogenesis is adapted to the degree of illness in intensive care unit patients. J Clin Endocrinol Metab 1988;67(2):223-7
70. Korsic M, Brinar V, Plavsic V, et al. Some aspects of adrenocortical stress response following stroke. Acta med Iugosl 1990; 44(2):137-45
71. Murros K, Fogelholm R, Kettunen S, Vuorela AL. Serum cortisol and outcome in ischemic brain infarction. J Neurol Sci 1993;116(1):12-17
72. Slowik A, Turaj W, Pankiewicz J, et al. Hypercortisolemia in acute stroke is related to the inflammatory response. J Neurol Sci 2002;196(1-2):27-32
73. Christensen H, Boysen G, Johannesen HH. Serum-cortisol reflects severity and mortality in acute stroke. J Neurol Sci 2004;217(2): 175-80
74. Anne M, Juha K, Timo M, et al. Neurohormonal activation in ischemic stroke: effects of acute phase disturbances on long-term mortality. Curr Neurovasc Res 2007;4(3):170-5
75. Neidert S, Katan M, Schuetz P, et al. Anterior pituitary axis hormones and outcome in acute ischaemic stroke. J Intern Med 2011;269(4):420-32
76. Schwartz S, Schwab S, Klinga K, et al. Neuroendocrine changes in patients with acute space occupying ischaemic stroke. J Neurol Neurosurg Psychiatry 2003;74(6): 725-7
77. Reding M, Orto L, Willensky P. The dexamethasone suppression test. An indicator of depression in stroke but not a predictor of rehabilitation outcome. Arch Neurol 1985;42(3):209-12
78. Fassbender K Schmidt R, Mossner R, Daffertshofer M, Hennerici M. Pattern of activation of the hypothalamic-pituitary-adrenal axis in acute stroke: relation to acute confusional state, extent of brain damage, and clinical outcome. Stroke 1994;25(6):1105-8
79. Barugh AJ, Gray P, Shenkin SD, et al. Cortisol levels and the severity and outcomes of acute stroke: a systematic review. J Neurol 2014;261(3):533-45.
80. Joynt RJ, Feibel JH, Sladek CM. Antidiuretic hormone levels in stroke patients. Ann Neurol 1981;9(2):182-4
81. Barreca T, Gandolfo C, Corsini G, et al. Evaluation of the secretory pattern of plasma arginine vasopressin in stroke patients. Cerebrovasc Dis 2001;11(2): 113-18
82. Preibisz JJ, Sealey JE, Laragh JH, et al. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983;5(2):I129-38
83. Katan M, Christ-Craina M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 2010;24(140):w13101
84. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005;26(12): 2500-4
85. Katan M, Fluri F, Morgenthaler NG, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009;66(6):799-808
86. Tu WJ, Dong X, Zhao SJ, et al. Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke. J Neuroendocrinol 2013;25(9):771-8
87. Zhang X, Lub XM, Huanga LF, Yea H. Copeptin is associated with one-year mortality and functional outcome in patients with acute spontaneous basal ganglia hemorrhage. Peptides 2012;33(2): 336-41
88. Fung C, De Marchis GM, Katan M, et al. Copeptin as a marker for severity and prognosis of aneurysmal subarachnoid hemorrhage. PLoS One 2013;8(1):e53191
89. De Marchis GM, Katan M, Weck A, et al. Copeptin adds prognostic information after ischemic stroke. Results from the CoRisk study. Neurology 2013;80(14):1278-86.
90. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3): 177-88
91. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56(2):455-63
92. Zweifel C, Katan M, Schuetz P, et al. Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage. BMC Neurol 2010;10:34
93. Yu WH, Wang WH, Dong XQ, et al. Prognostic significance of plasma copeptin detection compared with multiple biomarkers in intracerebral hemorrhage. Clin Chim Acta 2014;433C:174-8
94. Urwyler SA, Schuetz P, Fluri F, et al. Prognostic value of copeptin: one-year outcome in patients with acute stroke. Stroke 2010;41(7):1564-71
95. Tu WJ, Chen H, Cui LH. Prognostic value of copeptin in patients with acute ischemic stroke. Iran J Neurol 2011;10(3-4):58
96. Zhang JL, Yin CH, Zhang Y, et al. Plasma copeptin and long-term outcomes in acute ischemic stroke. Acta Neurol Scand 2013; 128(6):372-80
97. Dong X, Tao DB, Wang YX, et al. Plasma copeptin levels in Chinese patients with acute ischemic stroke: a preliminary study. Neurol Sci 2013;34(9):1591-5
98. Fluri F, Morgenthaler NG, Mueller B, et al. Copeptin, procalcitonin and routine inflammatory markers-predictors of infection after stroke. PLoS One 2012; 7(10):e48309
99. Ulm L, Ohlraun S, Harms H, et al. Stroke adverse outcome is associated with nosocomial infections (STRAWINSKI): procalcitonin ultrasensitive-guided antibacterial therapy in severe ischemic stroke patients - rationale and protocol for a randomized controlled trial. Int J Stroke 2013;8(7):598-603